Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.
Evogene Ltd. reports developments as a computational chemistry company focused on generative design of small molecules for pharmaceutical and agricultural applications. Its recurring updates center on ChemPass AI™, a proprietary generative AI platform used to explore chemical space and optimize small-molecule candidates across multiple parameters.
Company news also covers financial results, strategic refocusing around ChemPass AI™, collaborations in drug discovery and ag-chemical development, and subsidiary activity. Reported subsidiary themes include Casterra's castor seed varieties and castor farming systems for bio-based industries, AgPlenus work on novel herbicides and fungicides, Biomica microbiome-based therapeutics, and Nasdaq listing-compliance matters for EVGN ordinary shares.
Biomica Ltd., a clinical-stage biopharmaceutical company and a subsidiary of Evogene (NASDAQ: EVGN), announced that its CEO Dr. Elran Haber and VP R&D Dr. Shiri Meshner will attend the 7th Annual Microbiome Movement Drug Development Europe in London from January 31 to February 2, 2023. Dr. Haber will participate in two panel discussions, focusing on translating microbiome science into products and investor collaboration. Dr. Meshner's presentation, entitled Rationally Designed LBPs – From Computational & Pre-clinical Data to Clinical Studies, is scheduled for February 1, 2023. Both executives are available for one-on-one meetings at the conference.
Casterra Ag Ltd., a subsidiary of Evogene (Nasdaq: EVGN), has entered an agreement with a leading energy company to supply unique castor seed varieties for biofuel production. The primary focus includes seed purchases for cultivation in specific African territories, with the possibility of expanding cooperation. Castor biofuels are noted for their renewable, biodegradable properties and minimal environmental impact, being carbon-neutral. Casterra aims to provide genetically advanced seeds to meet eco-friendly energy needs, leveraging Evogene's GeneRator AI tech-engine for high-yield crops. This partnership could enhance Casterra's market position in the biofuel sector.
Biomica Ltd., a biopharmaceutical company under Evogene Ltd. (NASDAQ: EVGN), will participate in the J.P. Morgan Healthcare Week from January 9 to 11, 2023, in San Francisco. This follows a successful financing round of $20 million led by Shanghai Healthcare Capital. Dr. Elran Haber, CEO of Biomica, will be available for one-on-one meetings.
Biomica focuses on developing microbiome-based therapeutics for antibiotic resistance, immuno-oncology, and gastrointestinal disorders, utilizing a unique Computational Predictive Biology platform.
Biomica Ltd., a clinical-stage biopharmaceutical company and subsidiary of Evogene (Nasdaq: EVGN), announced a $20 million financing round led by Shanghai Healthcare Capital. This funding is essential for advancing Biomica's pipeline of microbiome-based therapeutics, including completing the phase 1 study of BMC128 and preparing for phase 1 trials of BMC333 aimed at treating inflammatory bowel disease. The financing is pending clearance from Chinese regulatory authorities.
Evogene Ltd. (Nasdaq: EVGN) has announced that Bayer will pay the company $3.5 million as part of their joint seed traits collaboration agreement. This payment is linked to a restructuring of patent obligations under the agreement, where Evogene licensed genes for specific seed traits targeting crops such as corn, soy, cotton, and canola. The collaboration aims to enhance the development of life-science products through Evogene's innovative technologies, including MicroBoost AI, ChemPass AI, and GeneRator AI.
Evogene Ltd. (Nasdaq: EVGN) reported its Q3 2022 financial results, revealing revenues of $466,000, significantly up from $151,000 year-over-year. The company maintains a solid cash position of approximately $38 million, expected to fund operations into late 2024. Noteworthy progress includes advancements in clinical trials for subsidiary Biomica's drug candidate and the submission of a registration package for Lavie Bio's bio-fungicide. The net loss for Q3 2022 was $7.2 million, improving from $8.3 million for the same quarter last year.
Casterra Ag Ltd., a subsidiary of Evogene (EVGN), has signed a long-term royalty agreement with Titan Castor Farms Limited in Zambia, enhancing its position in the global castor oil market valued at $1.2 billion. Casterra will supply advanced castor seeds and support Titan in establishing a castor oil production facility. This agreement is expected to drive growth in Zambian castor oil exports, starting in 2023. Both companies anticipate significant market synergies and progress within the growing African biofuel sector.
Biomica Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced its participation in the 7th Annual Microbiome Connect USA 2022 Summit on November 16-17, 2022, in Boston, MA. Dr. Elran Haber, Biomica's CEO, will join the panel discussion titled "Market Dynamics and Investment Landscape" on November 17 at 9:00 a.m. ET. The event aims to highlight drug development platforms utilizing microbiomes for disease prevention and treatment. Dr. Haber will also be available for one-on-one meetings during the conference.
Evogene Ltd. (NASDAQ: EVGN) has announced it will release its third-quarter 2022 financial results on November 17, 2022. A conference call is scheduled for 9:00 AM ET the same day. The call will discuss the financial results and can be accessed via phone or live webcast on the company's website. Evogene focuses on developing life-science products through its advanced technological engines, including MicroBoost AI, ChemPass AI, and GeneRator AI. The company aims to enhance product development efficiency while decreasing costs.
Lavie Bio Ltd., a subsidiary of Evogene (Nasdaq: EVGN), has submitted a registration package for its novel bio-fungicide, LAV.311, to the U.S. EPA. This product targets damaging fungal diseases like fruit rots and powdery mildews, addressing a $2 billion market in the U.S. alone. After over 30 successful field trials in various regions, LAV.311 is set for commercial launch in 2024. It promises a sustainable solution amidst declining availability of traditional fungicides, aligning with modern Integrated Pest Management practices.